Comparative Pharmacology
Head-to-head clinical analysis: LUCENTIS versus SUSVIMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUCENTIS versus SUSVIMO.
LUCENTIS vs SUSVIMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to and inhibits the biological activity of vascular endothelial growth factor A (VEGF-A), thereby preventing VEGF-A from interacting with its receptors (VEGFR1 and VEGFR2) on endothelial cells, reducing neovascularization and vascular permeability.
Ranibizumab is a humanized monoclonal antibody fragment that binds to and inhibits the activity of vascular endothelial growth factor A (VEGF-A), thereby reducing angiogenesis and vascular permeability.
Intravitreal injection of 0.5 mg (0.05 mL) once every 4 weeks (monthly).
10 mg administered via intravitreal injection every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life from vitreous humor: approximately 9 days (range 7–11 days) in humans. From serum: ~0.5 days (due to rapid systemic clearance). Clinical context: supports monthly intravitreal dosing.
Terminal elimination half-life is approximately 4.9 days (range 3.5–6.7 days) in patients receiving intravitreal injections every 4 weeks. The long half-life supports sustained intravitreal VEGF suppression with monthly dosing.
Primarily metabolized via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible due to high molecular weight (48 kDa). Fecal/biliary elimination not characterized. Systemic clearance ~0.81 mL/hr.
Primarily metabolized in the liver via catabolism to small peptides and amino acids; renal elimination of metabolites is negligible as intact drug is not excreted renally. Biliary/fecal excretion is not a significant route. <1% of dose excreted unchanged in urine.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor